Percutaneous coronary interventions in stable and acute

374 Pages·2015·7.54 MB·English

i
nP
ster
ac
bu
lt Percutaneous
ea
an
ne
o
d coronary interventions
u
as
cu c
to in stable and acute
er
co
on
ra coronary syndromes
or
ny
a in
r - stent technology,
yt
ser
ynve lesion complexity and
dn
rt
oio clinical outcome
mn
es
s
michael magro

Percutaneous coronary interventions in
stable and acute coronary syndromes
- stent technology, lesion complexity and
clinical outcome
Michael Magro
Layout and printing: Optima Communicatie, Rotterdam, The Netherlands
ISBN: 978-94-6169-621-2
Financial Support for printing of the thesis by
St Jude Medical
Biosensors
Biotronik
Percutaneous coronary interventions in
stable and acute coronary syndromes
- stent technology, lesion complexity and clinical outcome
Percutane coronaire interventies in
stabiele en acuut coronaire syndromes
– stent technologie, complexiteit laesie en klinische uitkomst
Proefschrift
Ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
Op gezag van de
rector magnificus
Prof.dr. H.A.P. Pols
en volgens besliut van het College voor Promoties
De openbare verdediging zal plaatsvinden op
dinsdag 20 januari 2015 om 13:30 uur
door
michael magro
geboren te Saint Julians, Malta
Promotie commissie
Promotoren:
Prof.dr. P.W.J.C. Serruys
Prof.dr. R.J. van Geuns
overige leden:
Dr. R. T. Van Domburg
Prof.dr. F. Zijlstra
Dr. M. Valgimigli
To my parents and my wife Alexia

table oF contents
introduction 15
Part i: coronary stents
chapter 1.1 drug eluting stents. 23
Garg S, Magro M, Serruys PW.
Chapter 232, textbook edited by E.Healy, Comprehensive
Biomaterials Wiley-Blackwell 2010
chapter 1.2 transferability of data between different drug-eluting 47
stents.
Magro M, Onuma Y, Silber S, Serruys PW.
EuroIntervention. 2009 Nov;5(5):527-31.
Part ii: Percutaneous revascularization in stable
coronary artery disease
chapter 2.1 revascularization treatment of stable coronary artery 55
disease.
Magro M, Garg S, Serruys PW.
Expert Opinion on Pharmacotherapy. 2011 Feb;12(2):195-212.
chapter 2.2 Four-year clinical outcome of sirolimus- and paclitaxel- 75
eluting stents compared to bare-metal stents for the
percutaneous treatment of stable coronary artery
disease.
Simsek C, Onuma Y, Magro M, de Boer S, Battes L, van
Domburg RT, Boersma E, Serruys PW; Interventional
Cardiologists of the Thoraxcenter (2000-2005).
Catheter Cardiovasc Interv. 2010 Jul 1;76(1):41-9.
Part iii: Percutaneous revascularization in ‘all comers’;
the imPortance oF stent tyPe
chapter 3.1 the unrestricted use of sirolimus- and Paclitaxel-eluting 89
stents results in better clinical outcomes during 6-years
Follow-up than bare-metal stents. an analysis from the
research and t-seacrh registries.
Simsek C, Magro M, Boersma E, Onuma Y, Nauta S, Gaspersz
M, van der Giessen W, van Domburg R, Serruys PW.
JACC Intv. Oct;3(10):1051-8.
chapter 3.2 very late coronary stent thrombosis of a newer- 99
generation everolimus-eluting stent compared with
early-generation drug-eluting stents: a prospective
cohort study.
Magro M, Raber L, Stefanini GG, Kalesan B, van Domburg RT,
Onuma Y, Wenaweser P, Daemen J, Meier B, Jüni P, Serruys PW,
Windecker S.
Circulation. 2012 Mar 6;125(9):1110-21.
chapter 3.3 long-term invasive follow-up of the everolimus-eluting 119
bioresorbable vascular scaffold: five-year results of
multiple invasive imaging modalities.
Simsek C, Karanasos A, Magro M, Garcia-Garcia HM, Onuma Y,
Regar E, Boersma E, Serruys PW, van Geuns RJ.
EuroIntervention. 2014 Oct 28. pii: 20130724-03.
Part iv: Percutaneous coronary interventions with
underlying metabolic disorders
chapter 4.1 long-term outcome of the unrestricted use of 131
everolimus-eluting stents compared to sirolimus-eluting
stents and paclitaxel-eluting stents in diabetic patients:
the bern-rotterdam diabetes cohort study.
Simsek C, Räber L, Magro M, Boersma E, Onuma Y, Stefanini
GG, Zanchin T, Kalesan B, Wenaweser P, Jüni P, van Geuns RJ,
van Domburg RT, Windecker S, Serruys PW
Int J Cardiol. 2013 Dec 5;170(1):36-42.